Form 4: Monopar Therapeutics: COO Andrew Cittadine Acquires Shares
Insider Transaction Filing
Monopar Therapeutics reports that Chief Operating Officer Andrew Cittadine acquired shares through the vesting and settlement of restricted stock units.
Summary
- Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, acquired 5,254 shares of common stock on June 30, 2026, through the vesting and settlement of restricted stock units (RSUs).
- Additionally, 2,309 shares were withheld by the issuer to cover applicable taxes due upon the vesting of RSUs.
- Following these transactions, Cittadine beneficially owns 57,923 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine insider transaction related to executive compensation rather than a significant strategic move or financial performance indicator.
Positives
- The Chief Operating Officer acquired additional shares, indicating continued commitment to the company.
- Vesting of RSUs suggests that performance or time-based conditions have been met.
Negatives
- 2,309 shares were withheld by the issuer for tax purposes, reducing the net shares received by the reporting person.
Future Outlook
The filing details the vesting schedules for various grants of restricted stock units, with full vesting dates extending to December 31, 2029. This indicates a long-term incentive structure for the reporting person.
Industry Context
StockSavvy.ai notes that insider transactions, such as the acquisition of shares by a Chief Operating Officer through RSU vesting, are common in the biotechnology and pharmaceutical sectors as a method of executive compensation and alignment with shareholder interests.
Stakeholder Impact
- Shareholders: The transaction reflects a standard compensation practice and does not immediately indicate a change in company strategy or financial health. The acquisition of shares by management can be seen as a positive alignment of interests.
- Employees: The vesting of RSUs for the COO reinforces the company's use of equity-based compensation, which may be a model for other employee incentive programs.
- Management: The transaction confirms the COO's continued role and compensation structure within the company.
Next Steps
- Continued vesting of restricted stock units according to the outlined schedules through December 31, 2029.
Key Dates
| Date | Description |
|---|---|
| 06/30/2026 | Transaction date for acquisition of common stock upon vesting and settlement of RSUs, and for shares withheld for taxes. |
| 02/01/2023 | Date of grant for a portion of the restricted stock units. |
| 03/04/2025 | Date of grant for another portion of the restricted stock units. |
| 12/02/2025 | Date of grant for a further portion of the restricted stock units. |
| 12/31/2026 | Full vesting date for RSUs granted on February 1, 2023. |
| 12/31/2028 | Full vesting date for RSUs granted on March 4, 2025. |
| 12/31/2029 | Full vesting date for RSUs granted on December 2, 2025. |
| 07/02/2026 | Date of filing of the Form 4. |
Keywords
Monopar Therapeutics, MNPR, Form 4, Insider Transaction, Restricted Stock Units, Share Vesting, Andrew Cittadine, Chief Operating Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.